|
Variable
|
Male
|
Female
|
P
|
|---|
|
Median age, years
|
|
Range
|
|
< 45
|
177(46.6%)
|
75(62.0%)
|
0.003
|
|
≥45
|
203(53.4%)
|
46(38.0%)
| |
|
Marital status
|
|
Married
|
17(4.5%)
|
6(5.0%)
|
0.833
|
|
Single
|
363(95.3%)
|
115(95.0%)
| |
|
Education years
|
|
No formal education
|
6(1.6%)
|
7(5.8%)
|
0.065
|
|
Primary level
|
49(12.9%)
|
20(16.5%)
| |
|
Secondary level
|
99(26.1%)
|
24(19.8%)
| |
|
High school
|
112(29.5%)
|
37(30.6%)
| |
|
University
|
114(30.0%)
|
33(27.3%)
| |
|
Smoking history
|
|
Ever
|
159(41.8%)
|
116(4.1%)
|
<0.0001
|
|
Never
|
221(58.2%)
|
5(95.9%)
| |
|
Alcohol history
|
<0.0001
|
|
Ever
|
53(13.9%)
|
0(0)
| |
|
Never
|
327(86.1%)
|
121(100.0%)
| |
|
ECOG score
|
0.174
|
|
0
|
378(99.7%)
|
118(99.2%)
| |
|
1
|
0(0)
|
1(0.8)
| |
|
2
|
1(0.3%)
|
0(0)
| |
|
WHO type
|
0.862
|
|
1
|
2(0.5%)
|
1(0.8%)
| |
|
2
|
2(0.5%)
|
1(0.8%)
| |
|
3
|
375(98.9%)
|
117(98.3%)
| |
|
T stage
|
0.521
|
|
1
|
19(5.0%)
|
3(2.5%)
| |
|
2
|
67(17.6%)
|
18(14.9%)
| |
|
3
|
202(53.2%)
|
71(58.7%)
| |
|
4
|
92(24.2%)
|
29(24.0%)
| |
|
N stage
|
0.641
|
|
0
|
50(13.2%)
|
11(9.1%)
| |
|
1
|
144(37.9%)
|
51(42.1%)
| |
|
2
|
146(38.4%)
|
45(37.2%)
| |
|
3
|
40(10.5%)
|
14(11.6%)
| |
|
AJCC stage
|
0.322
|
|
1
|
7(1.8%)
|
2(1.7%)
| |
|
2
|
44(11.6%)
|
7(5.8%)
| |
|
3
|
207(54.5%)
|
72(59.5%)
| |
|
4
|
122(32.1%)
|
40(33.1%)
| |
|
Treatment modality
|
|
RT
|
27(7.1%)
|
9(7.4%)
| |
|
IC + CCRT
|
194(51.1%)
|
60(49.6%)
| |
|
CCRT
|
159(41.8%)
|
52(43.0%)
| |
|
Median RT dose, Gy
|
|
VCA IgA
|
0.188
|
|
< 1:80
|
151(39.7%)
|
40(33.1%)
| |
|
≥ 1:80
|
229(60.3%)
|
81(66.9%)
| |
|
EA IgA
|
0.138
|
|
< 1:10
|
199(52.4%)
|
54(44.6%)
| |
|
≥ 1:10
|
181(47.6%)
|
67(55.4%)
| |
|
Pre-EBV DNA
|
0.526
|
|
≤ 4000
|
201 (52.9%)
|
60(49.6%)
| |
|
> 4000
|
179 (47.1%)
|
61(50.4%)
| |
|
Post-EBV DNA
|
0.780
|
|
negative
|
136(35.8%)
|
45(37.2%)
| |
|
positive
|
244(64.2%)
|
76(62.8%)
| |
|
Family history of NPC
|
0.252
|
|
yes
|
18(4.7%)
|
9(7.4%)
| |
|
no
|
362 (95.3%)
|
112(92.6%)
| |
- Abbrevations. No Number, ECOG Eastern Cooperative Oncology Group, WHO World Health Organization, AJCC American Joint Committee on Cancer, RT Radiotherapy, IC Induction chemotherapy, CCRT Concurrent chemoradiotherapy, EBV DNA Epstein-Barr virus deoxyribonucleic acid, NPC Nasopharyngeal carcinoma
